Since MPC produce the proteoglycan materials found in discs, Mesoblast envisages that the injection of MPC into a degenerated intervertebral disc will lead to replacement of the protoeglycan of cartilage. This approach, with its anticipated ease of application and lack of side-effects, should offer a relatively non-invasive and cost-effective therapy for patients with moderate or severe degenerative disc disease.